Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention

Carcinogenesis

Volumn 35, Issue 1, 2014, Pages 237-246

  Fischer, Jared M ^a   Schepers, Arnout G ^b,c   Clevers, Hans ^c   Shibata, Darryl ^d   Liskay, R Michael ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CRE RECOMBINASE; SULINDAC; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CELL DIVISION; CELL FATE; CELL GROWTH; CELL ISOLATION; CELLULAR DISTRIBUTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG DOSE INCREASE; GENE INACTIVATION; INTESTINE CRYPT; INTESTINE POLYP; LOW DRUG DOSE; MISMATCH REPAIR; MOUSE; NONHUMAN; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; REVERTANT; SINGLE DRUG DOSE; TARGET CELL; TUMOR VOLUME;

ABERRANT CRYPT FOCI; ADENOMA; AGE FACTORS; ANIMALS; BETA-GALACTOSIDASE; CHEMOPREVENTION; DNA REPAIR; GENES, APC; INTESTINAL NEOPLASMS; INTESTINES; MICE; MICE, TRANSGENIC; MUTATION; STEM CELLS; SULINDAC;

EID: 84891361272     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt296     Document Type: Article

References (56)

1. Vogelstein,B. et al. (1985) Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science, 227, 642-645.
2. Network,T.C.G.A. (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330-337.
3. Garcia,S.B. et al. (1999) Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J. Pathol., 187, 61-81.
4. Shen,L. et al. (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. J. Natl Cancer Inst., 97, 1330-1338.
5. Thliveris,A.T. et al. (2005) Polyclonality of familial murine adenomas: analyses of mouse chimeras with low tumor multiplicity suggest shortrange interactions. Proc. Natl Acad. Sci. USA, 102, 6960-6965.
6. Prevo,L.J. et al. (1999) p53-mutant clones and field effects in Barrett's esophagus. Cancer Res., 59, 4784-4787.
7. Leedham,S.J. et al. (2009) Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology, 136, 542-550.e6.
8. Milicic,A. et al. (2008) Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res., 68, 7760-7768.
9. Barker,N. et al. (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature, 457, 608-611.
10. Clarke,A.R. (2005) Studying the consequences of immediate loss of gene function in the intestine: APC. Biochem. Soc. Trans., 33(Pt 4), 665-666.
11. Fischer,J.M. et al. (2012) Different phenotypic consequences of simultaneous versus stepwise Apc loss. Oncogene, 31, 2028-2038.
12. Kwong,L.N. et al. (2009) APC and its modifiers in colon cancer. Adv. Exp. Med. Biol., 656, 85-106.
13. Barker,N. et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature, 449, 1003-1007.
14. Schepers,A.G. et al. (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science, 337, 730-735.
15. Thliveris,A.T. et al. (2011) Clonal structure of carcinogen-induced intestinal tumors in mice. Cancer Prev. Res. (Phila)., 4, 916-923.
16. Novelli,M.R. et al. (1996) Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science, 272, 1187-1190.
17. Kuraguchi,M. et al. (2006) Adenomatous polyposis coli (APC) is required for normal development of skin and thymus. PLoS Genet., 2, e146.
18. Zambrowicz,B.P. et al. (1997) Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of betagalactosidase in mouse embryos and hematopoietic cells. Proc. Natl Acad. Sci. USA, 94, 3789-3794.
19. Snippert,H.J. et al. (2010) Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell, 143, 134-144.
20. Sato,T. et al. (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature, 459, 262-265.
21. Miller,A.J. et al. (2008) Tractable Cre-lox system for stochastic alteration of genes in mice. Nat. Methods, 5, 227-229.
22. Sangiorgi,E. et al. (2008) Bmi1 is expressed in vivo in intestinal stem cells. Nat. Genet., 40, 915-920.
23. Fischer,J.M. et al. (2008) Visualizing loss of heterozygosity in living mouse cells and tissues. Mutat. Res., 645, 1-8.
24. Sato,T. et al. (2011) Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature, 469, 415-418.
25. Baker,S.M. et al. (1998) Enhanced intestinal adenomatous polyp formation in Pms2-/-;Min mice. Cancer Res., 58, 1087-1089.
26. Boolbol,S.K. et al. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56, 2556-2560.
27. Waddell,W.R. et al. (1983) Sulindac for polyposis of the colon. J. Surg. Oncol., 24, 83-87.
28. Giardiello,F.M. et al. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328, 1313-1316.
29. Beazer-Barclay,Y. et al. (1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis, 17, 1757-1760.
30. Hochedlinger,K. et al. (2004) Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev., 18, 1875-1885.
31. Cheng,H. et al. (1985) Whole population cell kinetics and postnatal development of the mouse intestinal epithelium. Anat. Rec., 211, 420-426.
32. Shoemaker,A.R. et al. (1995) N-ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. Cancer Res., 55, 4479-4485.
33. Prolla,T.A. et al. (1998) Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat. Genet., 18, 276-279.
34. Halberg,R.B. et al. (2007) Polyclonal tumors in the mammalian intestine: are interactions among multiple initiated clones necessary for tumor initiation, growth, and progression? Cell Cycle, 6, 44-51.
35. Fearon,E.R. et al. (1987) Clonal analysis of human colorectal tumors. Science, 238, 193-197.
36. Kosari,F. et al. (2012) Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer. Am. J. Pathol., 181, 34-42.
37. Ananthanarayanan,V. et al. (2006) Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer, 6, 73.
38. Yakoub,D. et al. (2010) Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res., 70, 9129-9136.
39. Svrcek,M. et al. (2010) Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. Gut, 59, 1516-1526.
40. Preston,S.L. et al. (2003) Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res., 63, 3819-3825.
41. Tomasetti,C. et al. (2013) Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc. Natl Acad. Sci. USA, 110, 1999-2004.
42. Calabrese,P. et al. (2004) Colorectal pretumor progression before and after loss of DNA mismatch repair. Am. J. Pathol., 164, 1447-1453.
43. Calabrese,P. et al. (2004) Pretumor progression: clonal evolution of human stem cell populations. Am. J. Pathol., 164, 1337-1346.
44. Qiu,W. et al. (2010) Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc. Natl Acad. Sci. USA, 107, 20027-20032.
45. Rothwell,P.M. (2013) Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits. Recent Results Cancer Res., 191, 121-142.
46. Stark,L.A. et al. (2007) Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis, 28, 968-976.
47. Ashktorab,H. et al. (2005) Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. Dig. Dis. Sci., 50, 1025-1032.
48. Yoshikawa,R. et al. (1995) Effect of aspirin on the induction of apoptosis in colorectal adenocarcinoma cell-lines. Oncol. Rep., 2, 361-364.
49. Rothwell,P.M. et al. (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, 379, 1602-1612.
50. Rothwell,P.M. et al. (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, 376, 1741-1750.
51. Wasan,H.S. et al. (1998) APC in the regulation of intestinal crypt fission. J. Pathol., 185, 246-255.
52. Bjerknes,M. et al. (1997) APC mutation and the crypt cycle in murine and human intestine. Am. J. Pathol., 150, 833-839.
53. Bjerknes,M. (1996) Expansion of mutant stem cell populations in the human colon. J. Theor. Biol., 178, 381-385.
54. Totafurno,J. et al. (1987) The crypt cycle. Crypt and villus production in the adult intestinal epithelium. Biophys. J., 52, 279-294.
55. Cummins,A.G. et al. (2008) Crypt fission peaks early during infancy and crypt hyperplasia broadly peaks during infancy and childhood in the small intestine of humans. J. Pediatr. Gastroenterol. Nutr., 47, 153-157.
56. Rothwell,P.M. et al. (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377, 31-41.